Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Cas9, the first Cas protein repurposed for cutting DNA, introduces double-strand breaks that recruit DNA repair machinery. Despite its successes, the CRISPR-Cas9 system has several limitations, ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

CRISPR-Cas9 gene editing relies on a guide RNA that binds to a desired ... Base and prime editing also spawn undesired effects that can only be spotted with scrupulous screening. “As a field, we don’t ...

This streamlined licensing option enables a broader spectrum of innovators to access CRISPR/Cas9 intellectual property ... high-throughput screening and functional genomics. Prof Emmanuelle ...

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.